Acacia Pharma is focused on the development of compounds for the prevention and treatment of nausea and vomiting following surgery and chemotherapy. The lead programme is in phase 3 clinical development.
Acceleron Pharma (NASDAQ: XLRN) is a clinical-stage biotechnology company developing ligand traps that target the endogenous ligands for the TGF superfamily of serine/threonine protein kinase receptors. The company’s lead compound luspatercept is in phase 3 clinical trials for the treatment of anemia associated with myelodysplastic syndrome (MDS) and thalassemia.
Biosyntia is a biotech startup within synthetic biology and metabolic engineering. Biosyntia develops biocatalysts at an unprecedented speed and efficiency by employing a patent pending high-throughput screening technology.
CRISPR Therapeutics (NASDAQ:CRSP) is developing transformative gene-based medicines for patients with serious diseases. The therapeutic approach is to cure diseases at the molecular level, using the breakthrough gene editing technology called CRISPR-Cas9.
Entasis Therapeutics is a spin out from Astra Zeneca. The company is developing novel antibiotics for treatment of severe Gram-negative infections. The focus is on developing new antibiotics to treat infections resistant to current treatments.
ERT is a cloud platform solutions provider that supports the capture of efficacy and safety endpoints, harmonises data from any clinical source system, and delivers real-time insights, for optimal clinical trial performance.
Evotec is a leading drug discovery outsourcing company with a global client base. By combining cutting edge research technologies with well-established drug-discovery tools the company progresses product ideas from target to clinic. Evotec supports an increasing demand for high quality innovation with improved efficiency in the drug discovery process.
Flexion (NASDAQ: FLXN) is a specialty pharmaceutical company focused on the development and commercialisation of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA) – a type of degenerative arthritis.
HTG Molecular Diagnostics (NASDAQ: HTGM) develops and sells its Edge instrument and assays for quantification of gene expression. The instrument and assays are used for clinical diagnostics and in research. The Edge instrument is being launched in the US.
Inventiva develops drugs targeting nuclear receptors, transcription factors and epigenetic modulators, an has a clinical pipeline of novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases.
Invuity (NASDAQ: IVTY) is a commercial stage medical technology company pioneering the use of advanced photonics to provide surgeons with improved direct visualisation of surgical cavities during minimally invasive and minimal access surgical procedures.
iRhythm Technologies (NASDAQ: IRTC) is a medical device company that develops and markets the ZIO® Service – an innovative cardiac monitoring and diagnostic solution, which uses a single-use wearable patch to detect cardiac arrhythmias.
Karus Therapeutics develops innovative therapies for the treatment of inflammation and cancer. The lead programmes are in pre-clinical development and focus on histone deacetylase and phosphoinositide 3-kinase inhibitors.
Lysogene SA is a leading gene therapy biotechnology company developing breakthrough treatments targeting severe genetic pathologies with Central Nervous System involvement and high unmet medical needs.
Lysogene has successfully completed a Phase 1/2 gene therapy study using its lead product in patients with Sanfilippo syndrome, which is a lethal pediatric neurodegenerative disorder with currently no treatment. It belongs to the group of Lysosomal Storage Disorders and affects 1:100,000 live births.
Nabriva Therapeutics (NASDAQ: NBRV) is focused on the research and development of novel anti-infective agents to treat serious infections. Nabriva’s lead product candidate, lefamulin is entering phase 3 clinical trials for the treatment of moderate to severe community-acquired bacterialpneumonia.
Nuvelution leverages its extensive knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring products to the market.
ObsEva develops innovative drugs for women’s reproductive medicine. The lead project is in phase 2 clinical development for enhancing embryo implantation and increasing the pregnancy rate in connection with assisted reproductive technologies.
Orphazyme develops novel therapeutics for the treatment of lysosomal storage diseases. The company is preparing the lead programme for a phase 2/3 registration-enabling clinical trial in Niemann-Pick disease type C.
Procept BioRobotics develops a new treatment for benign prostate hyperplasia based on image- guided and robotically-controlled water ablation of prostate tissue. The device is CE marked and a PMA study underway for US approval.
RSPR Pharma is a Swedish pharmaceutical company developing an oral anti-asthmatic drug providing mast cell control by inhibiting both induced and basal release of asthma mediators.
Asthma is an inflammatory condition affecting some 300 million people worldwide and despite gold standard therapy (inhaled corticosteroids, which do not target mast cells) only 50% of patients reach asthma control. The RSPR Pharma compound is currently in clinical development and is intended for patients not controlled by corticosteroids.
Synlab is the largest laboratory service provider in Europe offering a full range of medical laboratory services for both clinical practice and hospital sectors, as well as areas such as within environmental monitoring, food safety and veterinary practice support.
Verona Pharma (LSE: VRP) is a clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis.